A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A. Mayer, Georg A. Böhmig, Alexander Kainz et al.|New England Journal of Medicine|2024Cited by 151
Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant RecipientsBilgin Osmanodja, Eva Schrezenmeier|Journal of Clinical Medicine|2022Cited by 85
TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic SyndromeLina L. Kampf, Tobias Hermle, Ronen Schneider et al.|Journal of the American Society of Nephrology|2019Cited by 43
225.3: Randomized phase 2 trial of felzartamab in humoral transplant rejection.Katharina A. Mayer, Georg A. Böhmig, Eva Schrezenmeier et al.|Transplantation|2024Cited by 0